Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 3/20 | 0.40 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.33 |
| ▸ | DPYD | Q12882 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13321362 | 0.86 | TYMP (0.33) | KMT2AMEN1SMN1; SMN2TYMPDPYD | |
| SCHEMBL3415213 | 0.83 | DPYD (0.34) | KMT2ALMNATYMPUPP1DPYD | |
| SCHEMBL1838508 | 0.78 | UPP1 (0.53) | BLMUPP1DPYDHSD17B10 | |
| SCHEMBL9652779 | 0.78 | KDM4E (0.51) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL4094686 | 0.78 | TYMP (0.63) | BLMKMT2AMEN1ALDH1A1LMNA | |
| Iodacyclur SCHEMBL3412826 | 0.78 | BLM (0.51) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL1829505 | 0.77 | TK1 (0.47) | ALDH1A1UPP1HSD17B10 | |
| SCHEMBL1835707 | 0.77 | HTT (0.42) | BLMKMT2AMEN1LMNATYMP | |
| SCHEMBL13071184 | 0.75 | TYMP (0.37) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL13273574 | 0.74 | TYMP (0.43) | BLMKMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| EP-2322534-A1 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2011-05-18 | — | — | EP | disclosed |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | PHARMASSET, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-20040242533-A1 | Antiviral nucleosides | KUMAR, RAKESH (CA) | 2004-12-02 | — | — | US | disclosed |
| EP-1387850-A2 | ANTIVIRAL NUCLEOSIDES | Kumar, Rakesh (CA) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002094844-A2 | ANTIVIRAL NUCLEOSIDES | KUMAR RAKESH (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242533-A1 | Antiviral nucleosides | ENTPD5, DUT, ADA | BLM 1135/4885KMT2A 2808/4885MEN1 4065/4885 |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | PNP, ENTPD5, ADA | BLM 856/4885KMT2A 2396/4885MEN1 3138/4885 |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | UMPS, ENTPD5, TK1 | BLM 3490/4885KMT2A 313/4885MEN1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.